Inquis Medical

About Inquis Medical

Inquis Medical, Inc. is a clinical-stage medical device company located in Silicon Valley, established in 2020 by co-founders and co-CEOs Vahid Saadat and Mojgan Saadat. Vahid Saadat is a serial entrepreneur in the medical device field with a history of developing and commercializing products, including at Arrinex, which was acquired by Stryker. The company focuses on the management of venous thromboembolic diseases (VTE), which affect up to 900,000 people in the U.S. annually.

The company's business is centered on the development and future commercialization of its proprietary thrombectomy technology. A significant milestone was achieved in November 2024, when Inquis Medical secured $40 million in an oversubscribed Series B financing round. This funding, led by Marshall Wace with participation from existing investors like ShangBay Capital, is intended to support the completion of a pivotal clinical trial and prepare for the commercial launch of their main product in 2025.

The flagship product is the AVENTUS Thrombectomy System. This device is designed for the non-surgical removal of blood clots from vessels. A key feature is its proprietary TrueClot™ tissue-sensing technology, which provides real-time feedback to the operator, distinguishing between blood, clot, and the vessel wall. This is designed to improve precision during clot removal, reduce blood loss, and increase procedural efficiency compared to existing technologies. The system integrates navigation, aspiration, and a blood return system that filters and immediately returns the patient's blood.

Inquis Medical has received FDA 510(k) clearance for the AVENTUS system. Initially cleared for peripheral indications in late 2023, the clearance was expanded in June 2025 to include the treatment of pulmonary embolism (PE), following a successful pivotal IDE clinical study. The study, which enrolled 120 patients across 22 U.S. sites, met its primary safety and efficacy endpoints, showing no device-related major adverse events and significant improvements in right heart strain. The company plans to use its recent funding to launch the AVENTUS system commercially.